Estrella Immunopharma, Inc.

Equities

ESLA

US2975841048

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-27 pm EDT			5-day change	1st Jan Change
0.9831 ^USD	-0.90%		-0.90%	-11.43%

May. 15	Estrella Immunopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
Jan. 30	Estrella Immunopharma, Inc. announces an Equity Buyback for $1 million worth of its shares.	CI

Estrella Immunopharma, Inc. Auditor Raises 'Going Concern' Doubt

December 18, 2022

Estrella Immunopharma, Inc. filed its S-4/A on Dec 19, 2022 for the period ending Jun 30, 2022. In this report its auditor, Friedman LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Latest news about Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	May. 15	CI
Estrella Immunopharma, Inc. announces an Equity Buyback for $1 million worth of its shares.	Jan. 30	CI
Estrella Immunopharma, Inc. authorizes a Buyback Plan.	Jan. 29	CI
Estrella Immunopharma, Inc.(NasdaqCM:ESLA) added to S&P TMI Index	Dec. 18	CI
Estrella Immunopharma, Inc. Announces Changes to Fiscal Year End from December 31 to June 30	Nov. 14	CI
Top Premarket Gainers	23-10-24	MT
Estrella Biopharma, Inc. completed the acquisition of TradeUP Acquisition Corp. from TradeUP Acquisition Sponsor LLC and others in a reverse merger transaction.	23-09-28	CI
Estrella Immunopharma, Inc. Auditor Raises 'Going Concern' Doubt	22-12-18	CI

Chart Estrella Immunopharma, Inc.

Duration

Period

More charts

Company Profile

Estrella Immunopharma, Inc. is a preclinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ESTRELLA IMMUNOPHARMA, INC.	-11.43%	34.44M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs